A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Author:
B.A. Burtness,J. Manola,R. Axelrod,A. Argiris,A.A. Forastiere
Publication:
Annals of Oncology
Copyright © 2008 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.